Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome

Nazarbayev University351 enrolled

Overview

Metabolic syndrome: aetiology, pathogenesis, diagnosis, clinical management and prognosis

Purpose: To create the complex scientifically proved concept of Metabolic syndrome (МS) development based on elaboration of the new methods of clinical diagnostics of МS components and highly effective МS clinical management in comparative studying of clinical, laboratory and cost effectiveness. Participants and methods: This clinical study included 351 adults (184 female) in the Scientific research institute of cardiology and internal diseases (Almaty, the Republic of Kazakhstan). Statistical analysis was performed using Microsoft Excel-2008 in updating Lapach, Chubenko et al (2000) and SPSS for Windows v.17.0.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

351

Conditions

Metabolic Syndrome

Interventions

Xenical, Pionorm, Diroton, Diltiazem, AtorvastatinDRUG

Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day

"Analimentary detoxication"DIETARY_SUPPLEMENT

Vegetable and salt diet

Eligibility

Sex: ALLMin age: 25 YearsMax age: 74 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * written consent form * age\> 25 years * skinfold thickness \> 0,7 cm BP\> 130/85 mm Hg or a patient on antihypertensive medications fasting blood glucose \> 6.1 mmole/L, or 2-hour postprandial glucose level \> 11.1 mmole/L / or a patient with type 2 diabetes blood cholesterol \> 5.6 mmole/L possibility of treatment \> 6 months follow-up \> 1 year Exclusion Criteria: * complete immobilization of a patient (paresis /paralysis) * patients with severe concomitant diseases of the kidneys and (or) of the liver * early post-operative condition * mental illness * pregnancy * persons who are in prison * persons who are in military Armed Forces

Locations (1)

Republican Scientific Center for Emergency Medicine

Astana, Astana, Kazakhstan

Outcomes

Primary Outcomes

Blood Glucose Level

Fasting blood glucose (FBG) (mmole/L) and Two-hour postprandial glucose (THPG) (mmole/L) were measured.

Time frame: up to 12 weeks

Systolic/ Diastolic Blood Pressures (mm Hg)

Systolic and Diastolic Blood Pressures (mm Hg) was measured by manual/automatic tonometery

Time frame: up to 12 weeks

Secondary Outcomes

Lipid Profile

Blood sample for lipid profile (Cholesterol in mmole/L, High-density Lipoproteids in mmole/L, Triglycerides in mmole/L) was measured

Time frame: up to 12 weeks

Immunoassay Hormones in Blood

Immunoassay Insulin in the blood (in nU/L) was investigated

Time frame: up to 12 weeks

Immunoassay Cortisole in Blood

Immunoassay Cortisole in the blood (nmole/L) was measured

Time frame: up to 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.